These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2965 related articles for article (PubMed ID: 25945007)

  • 21. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy.
    Kaibori M; Ishizaki M; Matsui K; Kwon AH
    Am J Surg; 2012 Sep; 204(3):300-7. PubMed ID: 22591698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
    Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
    Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Features and Outcome of Surgical Patients with Non-B Non-C Hepatocellular Carcinoma.
    Wakiyama S; Matsumoto M; Haruki K; Gocho T; Sakamoto T; Shiba H; Futagawa Y; Ishida Y; Yanaga K
    Anticancer Res; 2017 Jun; 37(6):3207-3213. PubMed ID: 28551666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
    Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
    Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic utility of alpha-fetoprotein and des-gamma-carboxyprothrombin in nigerians with hepatocellular carcinoma.
    Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
    Niger J Clin Pract; 2017 Oct; 20(10):1267-1272. PubMed ID: 29192630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma.
    Nobuoka D; Kato Y; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Nakatsura T
    Oncol Rep; 2010 Aug; 24(2):521-8. PubMed ID: 20596642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal.
    Blank S; Wang Q; Fiel MI; Luan W; Kim KW; Kadri H; Mandeli J; Hiotis SP
    Ann Surg Oncol; 2014 Mar; 21(3):986-94. PubMed ID: 24232510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.
    Pang Q; Zhang JY; Xu XS; Song SD; Qu K; Chen W; Zhou YY; Miao RC; Liu SS; Dong YF; Liu C
    World J Gastroenterol; 2015 May; 21(18):5607-21. PubMed ID: 25987786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Half-Life of Serum Des-Gamma-Carboxy Prothrombin Is a Prognostic Index of Survival and Recurrence After Liver Resection for Hepatocellular Carcinoma.
    Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Uesaka K
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):921-928. PubMed ID: 27638677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma.
    Hayashi M; Shimizu T; Hirokawa F; Inoue Y; Komeda K; Asakuma M; Miyamoto Y; Takeshita A; Shibayama Y; Tanigawa N
    Am Surg; 2011 May; 77(5):572-8. PubMed ID: 21679590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical relevance of increased serum preneoplastic antigen in hepatitis C-related hepatocellular carcinoma.
    Yamashita S; Kato A; Akatsuka T; Sawada T; Asai T; Koyama N; Okita K
    World J Gastroenterol; 2020 Apr; 26(13):1463-1473. PubMed ID: 32308347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
    Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
    Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on the value of serum des-γ-carboxy prothrombin in predicting hepatocellular carcinoma recurrence after liver transplantation].
    Xu Y; Wang PX; Cheng JW; Huang XW; Zhou J; Fan J; Yang XR
    Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):918-923. PubMed ID: 33256276
    [No Abstract]   [Full Text] [Related]  

  • 38. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
    J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
    World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 149.